Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

677
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
677
Tumor Immunotherapy01:27

Tumor Immunotherapy

899
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
899
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

690
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
690
Vaccinations01:51

Vaccinations

49.6K
Overview
49.6K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

15.4K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.4K
Hybridoma Technology01:31

Hybridoma Technology

16.6K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
16.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Prognostic Value of Clinical and Pathological Response to Neoadjuvant Therapy in Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Systematic Review and Clinical Implications.

Cancers·2026
Same author

The need for a dedicated surgical consent framework for robotic telesurgery: a global call to action.

Journal of robotic surgery·2026
Same author

Exploring the relationship between interoception and mental body representation in Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Efficacy and safety of Serenoa repens in benign prostatic disorders: a systematic review of recent clinical evidence.

Drugs in context·2026
Same author

Re: Gallagher et al. RESECT, A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery. Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2025.09.4174.

European urology·2026
Same author

The Diagnostic Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Patients with Rising PSA After Radical Prostatectomy and Postoperative Radiotherapy: A Systematic Review and Meta-analysis.

European urology oncology·2026
Same journal

Bladder Foreign Body of Gastrointestinal Origin: A Case Report and Literature Review.

Archivos espanoles de urologia·2026
Same journal

Real-Time Shear Wave Elastography Combined With MRI-Ultrasound Cognitive Fusion Targeted Biopsy for Repeat Prostate Biopsy.

Archivos espanoles de urologia·2026
Same journal

Evaluating a DeepSeek-Based Case-Based Learning Approach for Teaching the Emergency Management of Urosepsis to Nursing Students.

Archivos espanoles de urologia·2026
Same journal

Association of Fibrosis-Related Gene Expression Profiles in Benign Ureteral Stricture Tissue With Restenosis After Ureteroplasty.

Archivos espanoles de urologia·2026
Same journal

Retrospective Comparison of Transurethral Prostatic Columnar Water Balloon Dilation and Pharmacotherapy for Moderate-to-Severe Benign Prostatic Hyperplasia: Efficacy, Safety and Compliance.

Archivos espanoles de urologia·2026
Same journal

Analysis of the Effect of Stepwise Refined Nursing on the Severity of Ureteral Stent-Related Symptom Clusters After Flexible Ureteroscopic Lithotripsy.

Archivos espanoles de urologia·2026
See all related articles

Related Experiment Video

Updated: Nov 27, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.5K

[BCG Immunotherapy, past, present and future.]

Óscar Rodríguez Faba1, Jorge Huguet Pérez2, Francesca Pisano1

  • 1Unidad de Urología Oncológica. Servicio de Urología. Universitat Autónoma de Barcelona. Fundació Puigvert. Barcelona. España.

Archivos Espanoles De Urologia
|December 3, 2020
PubMed
Summary
This summary is machine-generated.

Bacillus Calmette-Guérin (BCG) immunotherapy is a standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC). Despite its success, challenges include treatment resistance, BCG supply shortages, and unclear mechanisms, prompting research into novel therapies.

Keywords:
BCGImmunotherapyInmunoterapiaNon-muscle invasive bladder cancerTratamiento tumor vesicalTreatment bladder cancerTumor vesical no-músculo invasivo

More Related Videos

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

10.9K
Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
10:11

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Published on: January 31, 2018

9.6K

Related Experiment Videos

Last Updated: Nov 27, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.5K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

10.9K
Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
10:11

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Published on: January 31, 2018

9.6K

Area of Science:

  • Oncology
  • Immunotherapy
  • Urology

Background:

  • Bacillus Calmette-Guérin (BCG) has been a cornerstone adjuvant immunotherapy for high-risk non-muscle invasive bladder cancer (NMIBC) for over 40 years.
  • Despite its efficacy, a significant percentage of patients (up to 20%) progress to muscle-invasive disease, and global BCG supply shortages pose a challenge.
  • The precise mechanism of action of BCG remains incompletely understood, with ongoing debate regarding optimal dosing, strains, and combination therapies.

Purpose of the Study:

  • To provide a historical review of BCG's impact on NMIBC treatment.
  • To outline current guidelines for BCG therapy, including dosage, strains, and combination strategies.
  • To explore future directions in NMIBC treatment, considering ongoing clinical trials in systemic immunotherapy, vaccines, and gene therapy.

Main Methods:

  • Historical review of BCG's role in NMIBC treatment.
  • Analysis of current clinical guidelines and controversies.
  • Survey of emerging immunotherapies and therapeutic modalities.

Main Results:

  • BCG remains the recommended treatment for high-risk NMIBC and is a successful immunotherapy.
  • Significant challenges persist, including treatment failure, BCG shortages, and mechanistic uncertainties.
  • Research is actively exploring novel treatments like systemic immunotherapy, vaccines, and gene therapy.

Conclusions:

  • BCG has profoundly impacted NMIBC management but is associated with limitations and challenges.
  • Further research into BCG's mechanism and optimization is warranted.
  • The future of NMIBC treatment likely involves a combination of established therapies and innovative approaches like systemic immunotherapy and gene therapy.